secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2023-08-23T23:59:59+00:00
Accession:  0000950170-23-044036
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology completes all-stock acquisition of Apexigen for ~$10.7M
----------------------------------------------------------------------

- Pyxis issued ~4.3M shares (exchange ratio 0.1725) so Apexigen holders own ~10% of combined co.
- Acquisition adds clinically validated APXiMAB antibody-discovery platform and Phase 2 CD40 agonist sotigalimab (now PYX-107).
- Combined co. positions for next-gen ADC creation; cash runway extended into 1H 2025.
- Jakob Dupont, former Apexigen director, appointed to Pyxis board as independent Class III director.
- Development strategy and timelines for PYX-107 to be shared in 4Q23.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023044036/0000950170-23-044036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023044036/pyxs-20230823.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-044036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer